A novel therapeutic effect of statins on nephrogenic diabetes insipidus

Leonilde Bonfrate, Giuseppe Procino, David Q.H. Wang, Maria Svelto, Piero Portincasa

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Statins competitively inhibit hepatic 3-hydroxy-3-methylglutaryl-coenzyme A reductase, resulting in reduced plasma total and low-density lipoprotein cholesterol levels. Recently, it has been shown that statins exert additional 'pleiotropic' effects by increasing expression levels of the membrane water channels aquaporin 2 (AQP2). AQP2 is localized mainly in the kidney and plays a critical role in determining cellular water content. This additional effect is independent of cholesterol homoeostasis, and depends on depletion of mevalonate-derived intermediates of sterol synthetic pathways, i.e. farnesylpyrophosphate and geranylgeranylpyrophosphate. By up-regulating the expression levels of AQP2, statins increase water reabsorption by the kidney, thus opening up a new avenue in treating patients with nephrogenic diabetes insipidus (NDI), a hereditary disease that yet lacks high-powered and limited side effects therapy. Aspects related to water balance determined by AQP2 in the kidney, as well as standard and novel therapeutic strategies of NDI are discussed.

Original languageEnglish (US)
Pages (from-to)265-282
Number of pages18
JournalJournal of Cellular and Molecular Medicine
Volume19
Issue number2
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Aquaporin 2
Nephrogenic Diabetes Insipidus
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Therapeutic Uses
Kidney
Water
Mevalonic Acid
Aquaporins
Inborn Genetic Diseases
Sterols
Ion Channels
LDL Cholesterol
Oxidoreductases
Homeostasis
Cholesterol
Liver
Therapeutics

Keywords

  • Apical membrane
  • Aquaporin
  • Cholesterol-lowering drugs
  • HMG-CoA
  • Hypercholesterolaemia
  • Kidney
  • Nephrogenic diabetes insipidus
  • Vasopressin
  • Water channels

ASJC Scopus subject areas

  • Molecular Medicine
  • Cell Biology

Cite this

A novel therapeutic effect of statins on nephrogenic diabetes insipidus. / Bonfrate, Leonilde; Procino, Giuseppe; Wang, David Q.H.; Svelto, Maria; Portincasa, Piero.

In: Journal of Cellular and Molecular Medicine, Vol. 19, No. 2, 01.01.2015, p. 265-282.

Research output: Contribution to journalArticle

Bonfrate, Leonilde ; Procino, Giuseppe ; Wang, David Q.H. ; Svelto, Maria ; Portincasa, Piero. / A novel therapeutic effect of statins on nephrogenic diabetes insipidus. In: Journal of Cellular and Molecular Medicine. 2015 ; Vol. 19, No. 2. pp. 265-282.
@article{4975c4e462814495a9fa02ea7e35d2ba,
title = "A novel therapeutic effect of statins on nephrogenic diabetes insipidus",
abstract = "Statins competitively inhibit hepatic 3-hydroxy-3-methylglutaryl-coenzyme A reductase, resulting in reduced plasma total and low-density lipoprotein cholesterol levels. Recently, it has been shown that statins exert additional 'pleiotropic' effects by increasing expression levels of the membrane water channels aquaporin 2 (AQP2). AQP2 is localized mainly in the kidney and plays a critical role in determining cellular water content. This additional effect is independent of cholesterol homoeostasis, and depends on depletion of mevalonate-derived intermediates of sterol synthetic pathways, i.e. farnesylpyrophosphate and geranylgeranylpyrophosphate. By up-regulating the expression levels of AQP2, statins increase water reabsorption by the kidney, thus opening up a new avenue in treating patients with nephrogenic diabetes insipidus (NDI), a hereditary disease that yet lacks high-powered and limited side effects therapy. Aspects related to water balance determined by AQP2 in the kidney, as well as standard and novel therapeutic strategies of NDI are discussed.",
keywords = "Apical membrane, Aquaporin, Cholesterol-lowering drugs, HMG-CoA, Hypercholesterolaemia, Kidney, Nephrogenic diabetes insipidus, Vasopressin, Water channels",
author = "Leonilde Bonfrate and Giuseppe Procino and Wang, {David Q.H.} and Maria Svelto and Piero Portincasa",
year = "2015",
month = "1",
day = "1",
doi = "10.1111/jcmm.12422",
language = "English (US)",
volume = "19",
pages = "265--282",
journal = "Journal of Cellular and Molecular Medicine",
issn = "1582-1838",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - A novel therapeutic effect of statins on nephrogenic diabetes insipidus

AU - Bonfrate, Leonilde

AU - Procino, Giuseppe

AU - Wang, David Q.H.

AU - Svelto, Maria

AU - Portincasa, Piero

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Statins competitively inhibit hepatic 3-hydroxy-3-methylglutaryl-coenzyme A reductase, resulting in reduced plasma total and low-density lipoprotein cholesterol levels. Recently, it has been shown that statins exert additional 'pleiotropic' effects by increasing expression levels of the membrane water channels aquaporin 2 (AQP2). AQP2 is localized mainly in the kidney and plays a critical role in determining cellular water content. This additional effect is independent of cholesterol homoeostasis, and depends on depletion of mevalonate-derived intermediates of sterol synthetic pathways, i.e. farnesylpyrophosphate and geranylgeranylpyrophosphate. By up-regulating the expression levels of AQP2, statins increase water reabsorption by the kidney, thus opening up a new avenue in treating patients with nephrogenic diabetes insipidus (NDI), a hereditary disease that yet lacks high-powered and limited side effects therapy. Aspects related to water balance determined by AQP2 in the kidney, as well as standard and novel therapeutic strategies of NDI are discussed.

AB - Statins competitively inhibit hepatic 3-hydroxy-3-methylglutaryl-coenzyme A reductase, resulting in reduced plasma total and low-density lipoprotein cholesterol levels. Recently, it has been shown that statins exert additional 'pleiotropic' effects by increasing expression levels of the membrane water channels aquaporin 2 (AQP2). AQP2 is localized mainly in the kidney and plays a critical role in determining cellular water content. This additional effect is independent of cholesterol homoeostasis, and depends on depletion of mevalonate-derived intermediates of sterol synthetic pathways, i.e. farnesylpyrophosphate and geranylgeranylpyrophosphate. By up-regulating the expression levels of AQP2, statins increase water reabsorption by the kidney, thus opening up a new avenue in treating patients with nephrogenic diabetes insipidus (NDI), a hereditary disease that yet lacks high-powered and limited side effects therapy. Aspects related to water balance determined by AQP2 in the kidney, as well as standard and novel therapeutic strategies of NDI are discussed.

KW - Apical membrane

KW - Aquaporin

KW - Cholesterol-lowering drugs

KW - HMG-CoA

KW - Hypercholesterolaemia

KW - Kidney

KW - Nephrogenic diabetes insipidus

KW - Vasopressin

KW - Water channels

UR - http://www.scopus.com/inward/record.url?scp=84921632833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921632833&partnerID=8YFLogxK

U2 - 10.1111/jcmm.12422

DO - 10.1111/jcmm.12422

M3 - Article

C2 - 25594563

AN - SCOPUS:84921632833

VL - 19

SP - 265

EP - 282

JO - Journal of Cellular and Molecular Medicine

JF - Journal of Cellular and Molecular Medicine

SN - 1582-1838

IS - 2

ER -